Three New Members to Join SLAS Board of Directors

Published: Dec 23, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO — The Society for Laboratory Automation and Screening (SLAS) announces the addition of three new members to the nine-­-member SLAS Board of Directors. Each will serve a three-­-year term, beginning Jan. 1, 2014.

Alastair Binnie, Bristol-­-Myers Squibb, Lawrenceville, NJ (USA)

Alastair Binnie is an executive leader with over 15 years of experience leading multi-­-disciplinary technology functions in pharmaceutical discovery and exploratory clinical research. In his current role at Bristol-­-Myers Squibb as vice president, Research Informatics and Automation, he leads a diverse organization responsible for a broad technology agenda supporting all research functions at BMS, including planning, delivering and supporting scientific IT platforms, laboratory automation, instrument support services, scientific computing infrastructure and architecture and software engineering.

Richard M. Eglen, Corning Life Sciences, Corning, NY (USA)

Richard Eglen is currently vice president and general manager at Corning Life Sciences. He possesses more than three decades of professional experience in technical and executive leadership roles at both drug discovery and technology discovery organizations. His current responsibilities include setting strategic direction and serving as general manager of Corning Life Sciences.

Michael Snowden, AstraZeneca, Essex, England (UK)

Michael (Mike) Snowden is vice president, Discovery Sciences within Innovative Medicines at AstraZeneca. A biochemist by trade, he possesses more than 25 years’ experience across a wide array of technological and scientific disciplines related to pre-­-clinical drug discovery. Dr. Snowden has an impressive track record of expert matrix management as well as strategic business development.

Binnie, Eglen and Snowden will fill vacancies created by three existing SLAS Board members, whose three-­-year terms of service conclude on Dec. 31, 2013:

• David Dorsett of Bristol-­-Myers Squibb, Princeton, NJ (USA)

• Jeff Paslay, Ph.D., of Paslay Consulting Group, Kirkland, WA (USA)

• Mary Jo Wildey, Ph.D., Merck Research Labs, Kenilworth, NJ (USA)

“SLAS is proud to endorse its new leaders and grateful for the years of service contributed by those completing their terms,” says 2013 SLAS President Jeff Paslay. “These transitions reinforce the stability of our Society’s governance structure, which ensures continued growth and momentum by balancing sound leadership with an annual influx of fresh thoughts and ideas.”

The confirmation process for Binnie, Eglen and Snowden was conducted in accordance with SLAS bylaws, policies, procedures and strategic plan. The process began with an open call for nominations in September and October. The SLAS Nominations Committee carefully considered proposed candidates in October. In November, final recommendations were approved by the SLAS Board of Directors and presented to the SLAS membership for consideration and comment.

For more information visit, contact SLAS Global Headquarters at +1.877.990.SLAS (5727) or e-­-mail

The Society for Laboratory Automation and Screening (SLAS) is an international community of more than 15,000 individual scientists, engineers, researchers, technologists and others from academic, government and commercial laboratories. The SLAS mission is to be the preeminent global organization providing forums for education and information exchange and to encourage the study of, and improve the practice of laboratory science and technology. For more information, visit

Help employers find you! Check out all the jobs and post your resume.

Back to news